Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Osicare-DS
- Development stage
- Unknown
- Lead developer
- Systopic Laboratories
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Osicare-DS is a branded generic formulation of glucosamine sulfate (1000 mg) developed and marketed by Systopic Laboratories. It is primarily indicated for the management of osteoarthritis, helping to reduce joint pain, stiffness, and swelling while supporting overall joint mobility and flexibility. Glucosamine sulfate is a naturally occurring amino sugar that serves as an essential building block for the synthesis of glycosaminoglycans and proteoglycans, which are critical components of the cartilage matrix and synovial fluid. By providing these structural precursors, Osicare-DS helps maintain cartilage integrity, promote joint repair, and exert mild anti-inflammatory effects to alleviate symptoms of degenerative joint diseases.
- Brand names
- Osicare-DS
- Other names
- Osicare DS
Beyond the preview
Go deeper on Osicare-DS.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Osicare-DS.